Work

Tamoxifen Initiation After Ductal Carcinoma In Situ

Year: 2020

Type: article

Study design: Observational Study

Abstract: Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after DCIS over a 15-year period in an integrated health care setting to identify factors related to initiation.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/9wzv-p171

Authors: Bowles, Erin J. A., Nichols, Hazel B., Stürmer, Til, Madziwa, Lawrence, Islam, Jessica, Buist, Diana S. M., Tran, Diem-Thy

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: G1353929375, G5117928749, North Carolina Translational & Clinical Sciences Institute (NC TraCS), CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems, Advancing Risk-based Breast Cancer Screening and Surveillance in Community Practice

OpenAlex ID: W4297931395

FWCI:

Cites:

Cited by:

Related to: 10